News and Trends 5 Nov 2019 UK Scientists Speed up Brain Cancer Diagnosis with AI A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people […] November 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2019 AI-Driven Antibiotic Susceptibility Test Launched in Austria Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […] October 28, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 25 Oct 2019 This UK AI Tool Researches Diseases for Drug Discovery Companies The Manchester-based company Biorelate is developing artificial intelligence (AI) technology that can collect biological data from the internet and speed up the drug discovery process. Mission: Develop AI technology that trawls the web for disease and drug data and collects it together like researchers would do manually in drug discovery. Biorelate’s product is able to […] October 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech London-based LabGenius has secured €8.9M in Series A funding, which the company plans to use to scale up its AI- and robotics-based drug development technology. LabGenius focuses on developing protein-based therapeutics using its ‘robot scientist’ EVA. “By transforming how these drugs are discovered, we have a shot at improving the lives of countless people,” said […] October 24, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2019 Channeling the Power of AI into Personalizing Medicine Artificial intelligence has been much discussed of late, but will it really help us solve important problems like how to bring personalized medicine to as many patients as possible? Kate Hilyard, COO of Healx in Cambridge in the UK, believes it can. Getting a drug to clinical trials currently requires a large investment of both […] October 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2019 UK Firm Raises €51M to Repurpose Drugs for Rare Diseases Using AI The Cambridge-based artificial intelligence company Healx has raised a Series B round of €50.8M to launch an AI tool that reduces the time it takes to develop treatments for rare diseases by five years. The Series B round was led by the UK VC firm Atomico and includes the returning investor Jonathan Milner, the founder […] October 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 IBM’s Watson for Genomics Launches in First European Hospital The Hôpitaux Universitaires Genève in Switzerland will be the first European university hospital to implement IBM’s artificial intelligence to help doctors select treatments for complex cancer cases. “Artificial intelligence could empower our clinicians to increase the speed of diagnosing their patients,” said Rodolphe Meyer, who is responsible for the IT department of […] September 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […] August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […] May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2019 Swiss Multi-Cancer Diagnostic Test Approved in Europe A cancer test developed by the Swiss company SOPHiA GENETICS has been approved for diagnosing multiple types of solid tumors by looking at genetic variations in 42 genes. SOPHiA GENETICS works in data-driven medicine, using huge amounts of genomic data to diagnose and personalize treatments to a patient. This new technology is being adopted by […] April 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […] March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […] March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email